Metamizol Kalceks (Metamizole Sodium Monohydrate)

Metamizole exerts its effect by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production in peripheral tissues. In addition, it influences central pain pathways in the spinal cord, providing analgesic and antipyretic actions without engaging opioid receptors.

The specific dose of Metamizol Kalceks is determined by the prescribing clinician based on the patient’s condition, age, weight, and clinical response. Healthcare professionals adjust the amount and frequency to achieve effective pain or fever control while monitoring safety.

Safety data for metamizole in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit justifies the potential risk. Clinicians should assess individual circumstances and consider alternative therapies when treating pregnant or nursing patients.

To order Metamizol Kalceks, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Metamizole offers potent analgesia and antipyresis comparable to strong NSAIDs but without the typical gastrointestinal ulcer risk. Unlike opioids, it does not cause respiratory depression, yet it carries a rare risk of agranulocytosis. Its rapid onset makes it useful for severe pain where NSAIDs are insufficient and opioids are undesirable.

Metamizol Kalceks must be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. The product should remain in its original packaging until use, and any opened vial should be administered promptly to maintain sterility and potency.

Metamizol Kalceks is given by intramuscular or intravenous injection. The solution is drawn into a sterile syringe, and the dose is administered slowly to reduce the risk of hypotension. Healthcare professionals follow aseptic technique and monitor the patient for immediate reactions during and after injection.

The most serious adverse events associated with Metamizole include agranulocytosis, which can lead to severe infections, and life‑threatening allergic reactions such as anaphylaxis or severe skin disorders like Stevens‑Johnson syndrome. Prompt recognition of symptoms such as fever, sore throat, rash, or breathing difficulty is essential for immediate medical intervention.

Metamizol Kalceks is contraindicated in patients with known hypersensitivity to metamizole or other pyrazolones, those with a history of agranulocytosis or severe blood dyscrasias, and individuals with uncontrolled hypotension. Caution is also advised for patients with severe hepatic or renal impairment.